Testing effectiveness (Phase 2)Ended earlyNCT03382977
What this trial is testing
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
Who this might be right for
Glioblastoma Multiforme
VBI Vaccines Inc. 70